Poor prognosis acute myelogenous leukemia 2--biological and molecular biological characteristics and treatment outcome.
Biological and molecular biological studies were performed on the marrow cells of 25 patients with poor prognosis AML to both characterize this type of leukemia and to assess the relationship between the parameters which were measured and treatment outcome. Treatment failure associated with high levels of telomerase activity and low levels of IL6 transcripts. Studies of the effects of amifostine on these parameters demonstrated that this agent reduced telomerase activity in aspirates of AML marrows. These data suggest that the beneficial effect associated with the administration of amifostine after the end of chemotherapy is likely, to be due to a reduction in the rate at which the surviving leukemia cells repopulate the marrow.
Li
B
B
Rush Cancer Institute, 1725 West Harrison Street, Suite 809, Chicago, IL 60612, USA.
Yang
J
J
Tao
M
M
Nayini
J
J
Horvath
E
E
Chopra
H
H
Meyer
P
P
Venugopal
P
P
Preisler
H D
HD
D004999:Amifostine / Q000627:therapeutic use*; D001483:Base Sequence; D017931:DNA Primers; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology*; D011379:Prognosis; D016896:Treatment Outcome
D017931:DNA Primers; D004999:Amifostine